Navigate with confidence with a motion-compensated, real-time view of the coronary arteries. All while protecting patients at risk of AKI and CIN. Learn more: https://lnkd.in/gdcid6BM * Demonstrated in a multi-center, randomized clinical trial. Hennessey B, et al., Dynamic Coronary Roadmap versus standard angiography for percutaneous coronary intervention: the randomised, multicentre DCR4Contrast trial. EuroIntervention. 2024 Feb 5;20(3):e198-e206.
Anthony Adair, CCDS’ Post
More Relevant Posts
-
Navigate with confidence with a motion-compensated, real-time view of the coronary arteries. All while protecting patients at risk of AKI and CIN. Learn more: https://lnkd.in/gScsGQ39 * Demonstrated in a multi-center, randomized clinical trial. Hennessey B, et al., Dynamic Coronary Roadmap versus standard angiography for percutaneous coronary intervention: the randomised, multicentre DCR4Contrast trial. EuroIntervention. 2024 Feb 5;20(3):e198-e206.
-
-
Human Resources Management | Employee Experience| Employer Branding | Employee Engagement
Navigate with confidence with a motion-compensated, real-time view of the coronary arteries. All while protecting patients at risk of AKI and CIN. Learn more: https://lnkd.in/gNwdCzgY * Demonstrated in a multi-center, randomized clinical trial. Hennessey B, et al., Dynamic Coronary Roadmap versus standard angiography for percutaneous coronary intervention: the randomised, multicentre DCR4Contrast trial. EuroIntervention. 2024 Feb 5;20(3):e198-e206.
-
-
Navigate with confidence with a motion-compensated, real-time view of the coronary arteries. All while protecting patients at risk of AKI and CIN. Learn more: https://lnkd.in/dSzkpyat * Demonstrated in a multi-center, randomized clinical trial. Hennessey B, et al., Dynamic Coronary Roadmap versus standard angiography for percutaneous coronary intervention: the randomised, multicentre DCR4Contrast trial. EuroIntervention. 2024 Feb 5;20(3):e198-e206.
-
-
Navigate with confidence with a motion-compensated, real-time view of the coronary arteries. All while protecting patients at risk of AKI and CIN. Learn more: https://lnkd.in/gccRFtbJ * Demonstrated in a multi-center, randomized clinical trial. Hennessey B, et al., Dynamic Coronary Roadmap versus standard angiography for percutaneous coronary intervention: the randomised, multicentre DCR4Contrast trial. EuroIntervention. 2024 Feb 5;20(3):e198-e206.
-
-
Collaborating with Healthcare Senior Leadership to bring Innovate Solutions to Critical Healthcare Challenges
Navigate with confidence with a motion-compensated, real-time view of the coronary arteries. All while protecting patients at risk of AKI and CIN. Learn more: https://lnkd.in/eaSRCmmz * Demonstrated in a multi-center, randomized clinical trial. Hennessey B, et al., Dynamic Coronary Roadmap versus standard angiography for percutaneous coronary intervention: the randomised, multicentre DCR4Contrast trial. EuroIntervention. 2024 Feb 5;20(3):e198-e206.
-
-
Corporate communication | Master's in Social Innovation | Diversity, equity & inclusion advocate | Education | Content Creator | Digital Marketing | Storytelling | Change Management
Navigate with confidence with a motion-compensated, real-time view of the coronary arteries. All while protecting patients at risk of AKI and CIN. 📌Learn more: https://lnkd.in/eifWdYg3 * Demonstrated in a multi-center, randomized clinical trial. Hennessey B, et al., Dynamic Coronary Roadmap versus standard angiography for percutaneous coronary intervention: the randomised, multicentre DCR4Contrast trial. EuroIntervention. 2024 Feb 5;20(3):e198-e206.
-
-
Compelling results of the RESCUE II Clinical Trial were recently presented during TCT 2024. Dr. Christian Bichard shared data from patients with acute intermediate-risk pulmonary embolism (PE) treated with the BASHIR™ Endovascular Catheter. Conducted at Temple University by Drs. Riyaz Bashir and Vladimir Lakhter, the study highlights the effectiveness of single-session pharmacomechanical lysis (PML) without the need for post-procedural thrombolytic infusion. #Thrombolex https://lnkd.in/eNUhhr37
-
-
News alert! Perspective presented the following data at the 2024 NANETS Multidisciplinary NET Medical Symposium today: - [212Pb]VMT-α-NET continued to have a favorable safety profile, with no dose-limiting toxicities observed at the two doses tested (2.5 and 5.0 mCi) - Eight of nine patients had durable control of disease. Six of nine patients had a measurable reduction of tumor volume, one of whom had a confirmed response as defined by RECIST v1.1. Perspective is continuing all required activities to pursue dose escalation according to Safety Monitoring Committee recommendations; recruitment is ongoing at 5.0 mCi. See here for more details: https://lnkd.in/eruWq3-7
-
-
Earlier this year, we announced the launch of our latest medical device, Cleerly ISCHEMIA, for the evaluation of symptomatic suspected coronary artery disease (CAD). How does Cleerly ISCHEMIA perform in large-scale clinical studies? Findings from a recently published article in the JACC Journals highlight the value of our AI-guided coronary CTA evaluation. This research validates that Cleerly ISCHEMIA demonstrates: - Higher diagnostic performance than other available non-invasive tests - Independent prognostic utility beyond other available non-invasive tests - Comprehensive lesion-by-lesion mapping across the entire length of the coronary vessel for actionable CAD metrics Cleerly strives to make innovative solutions that support healthcare professionals to improve diagnosis and prognostic risk stratification for patients with suspected CAD. #yesCCT https://lnkd.in/gqrg5-mi
-
-
#FORZA trial: 5-year clinical outcomes 📉 For the management of patients with angiographically intermediate coronary stenosis, #OCT and #FFR guidance had a similar risk of MACE at 5 years Thrilled to share our manuscript just published in the European Heart Journal #EHJ
